SFC Fluidics focuses on developing advanced technologies aimed at improving diabetes care and addressing other disease states. One of their key innovations is the proprietary ePump, which is designed to enhance insulin delivery systems. This next-generation device aims to provide more efficient and effective management of diabetes, ultimately leading to better clinical outcomes and reduced treatment costs. The company emphasizes the importance of addressing the significant financial burden diabetes places on global healthcare systems, highlighting a substantial market opportunity for their solutions.

Another notable technology from SFC Fluidics is the Gemini Dual-Hormone Automated Pump (AP), which represents a significant advancement in diabetes management. This system is engineered to deliver both insulin and glucagon, allowing for more precise control of blood glucose levels. By integrating dual-hormone therapy into a single device, SFC Fluidics aims to improve patient outcomes and simplify the management of diabetes, thereby addressing the complexities associated with traditional treatment methods.

United States

SFC Fluidics, Inc. has a mission to advance healthcare and improve quality of life through our enabling microfluidic technologies. The company's vision is to become a recognized global leader in the drug delivery, with a focus on insulin, and health monitoring markets where our unique product lines improve lifestyle and affordability.  SFC Fluidics® is a VIC Technology Venture Development™ portfolio company.

SFC Fluidics

Company Details